Related Experiment Video
Updated: Nov 7, 2025
06:21
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
1.8K
COVID-19 Vaccine and Hyperosmolar Hyperglycemic State
Mohammed A Abu-Rumaileh1, Ahmad M Gharaibeh1, Naser Eddin Gharaibeh2,3
1Endocrinology, University of Jordan School of Medicine, Amman, JOR.
Cureus
|April 30, 2021
Summary
This case study reports new-onset diabetes type 2 in a patient following COVID-19 vaccination. It explores potential mechanisms linking the virus and vaccine to diabetes development.
Area of Science:
- Endocrinology
- Virology
- Immunology
Background:
- Coronavirus disease 2019 (COVID-19) is a multi-system illness with diverse complications.
- A known complication is the development or unmasking of diabetes mellitus.
- The pancreatic angiotensin-converting enzyme 2 (ACE2) receptor is implicated in COVID-19 pathophysiology and diabetes.
Observation:
- A case of new-onset type 2 diabetes mellitus presenting as hyperosmolar hyperglycemic state (HHS) is presented.
- The patient developed HHS after receiving a COVID-19 vaccine.
- This presentation suggests a potential link between vaccination and diabetes onset.
Findings:
- The study reviews potential mechanisms by which COVID-19 may lead to new-onset type 2 diabetes.
- The role of the ACE2 receptor in the pancreas is explored.
- The temporal association between COVID-19 vaccination and HHS is highlighted.
Implications:
- This case highlights a potential adverse effect of COVID-19 vaccination.
- Further research is needed to elucidate the exact mechanisms linking COVID-19, its vaccines, and new-onset diabetes.
- Understanding these mechanisms is crucial for patient management and vaccine safety monitoring.
More Related Videos
Related Concept Videos
01:15Hypoglycemia and Glucagon
506
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
506
01:15Diabetes: Symptoms, Diagnosis, and Complications
1.4K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
1.4K
01:19Overview of Carbohydrate Metabolism
2.4K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
2.4K
01:22Diabetes Mellitus: Type 2 and Gestational
3.7K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.7K
01:06Oral Hypoglycemic Agents: Glinides
354
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
354
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
400
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
400